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Abstract 
Mesenchymal stem cells (MSCs) have exciting medical potential, especially those that 
are genetically modified. Non-viral methods for genetic modification present several advantages 
over viral methods, and hence, such methods have been optimized for MSCs from a variety of 
species. Although equine MSCs have great importance, prior to this study, effective non-viral 
transfection parameters for these cells had not been determined. Here both chemical and physical 
transfection methods were optimized for equine MSCs, using red fluorescent protein as a 
reporter gene. Chemical reagents were optimized for reagent-to-DNA ratio, transfection solution 
plating volume, and cell density. Additionally, ideal voltage, cell concentration, DNA 
concentration, buffer, and pulse number settings were discovered for electroporation. The 
method resulting in highest gene expression was electroporation with one 30-msec pulse at 170 
volts in Opti-Mem buffer. This technique resulted in transfection of 54% of the cell population, a 
percentage that is on the higher end of nonviral MSC transfection efficiencies. The transfection 
parameters determined in this study will undoubtedly be useful to all researchers who wish to 
genetically modify equine MSCs.  
 
Keywords: cationic lipid, electroporation, equine, gene therapy, mesenchymal stem cells, 
nonviral gene transfer, optimize, transfection 
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Introduction 
Mesenchymal stem cells (MSCs) have exciting medical potential, because they can be 
readily isolated, quickly expanded, and induced to differentiate along diverse pathways. MSCs 
have been obtained from many tissues, including bone marrow, skeletal muscle, pancreas, 
adipose tissue, synovium, primary teeth, and brain, and can differentiate into adipocytes, 
osteocytes, myocytes, chondrocytes, neurons, and hepatocytes1, 2. They have been used 
experimentally to treat a number of conditions, from spinal cord, cartilage, and tendon injuries, 
to coronary artery disease, muscular dystrophy, lung damage, stroke, Parkinson’s Disease, and 
anemia3. MSCs are identified according to their adherence to plastic under standard culture 
conditions, their expression of CD105, CD73 and CD90, their lack of expression of CD45, 
CD34, CD14 or CD11b, CD79-alpha or CD19 and HLA-DR surface molecules, as well as by 
their differentiation capabilities4.  
Many medical applications of MSCs involve genetic modification. For instance, MSCs 
overexpressing CXC chemokine receptor 4 migrated towards the infarcted region of rat hearts 
more than unmodified MSCs, and helped in the myocardial repair process5. MSCs expressing 
tumor necrosis factor apoptosis ligand (TRAIL) had anti-cancer effects in malignant human 
glioma models6. Arthritic mice treated with interleukin-10-transduced MSCs had significantly 
decreased arthritis severity compared to mice treated with MSCs alone7. These and many other 
studies demonstrate the wide-ranging possibilities for medical use of modified MSCs.  
 The introduction of foreign DNA into MSCs can be achieved through viral or non-viral 
methods. Viral transduction is no doubt effective, and can result in close to 100% gene 
expression under certain conditions8. But the use of viruses as gene delivery vehicles has 
disadvantages, such as the high risk of an immune reaction against the virally-modified cells, or 
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the potential for random integration of the transgene into the patient’s genome, which could lead 
to harmful or lethal mutations9. In a famous and tragic incident, 18-year-old Jesse Gelsinger died 
after an injection of 2.8 x 1013 adenovirus particles into his liver. These viruses carried a gene 
meant to correct his ornithine transcarbamylase deficiency10. Since then, researchers have made 
substantial progress in developing viral vectors and delivery methods that are better suited to 
gene therapy applications, including advances to prevent immune responses from lentiviral, 
adenoviral, and adeno-associated virus-mediated gene transfer11. However, another promising 
option is to simply avoid the use of viral methods altogether. Non-viral transfection techniques 
have several advantages, including lower immunogenicity, lower toxicity, and less restriction on 
size of construct to be transferred12. 
Because of these advantages, a vast number of non-viral techniques for introducing DNA 
into cells have been developed. Two of the most common methods are lipofection, in which 
cationic lipids surround the DNA and facilitate its entrance into the cell, and electroporation, in 
which an electric field induces formation of pores in the plasma membrane, through which DNA 
can enter13,14. A less-common physical method is sonoporation, in which ultrasonic waves are 
used to disrupt the cell membrane and allow entry of DNA into the cell15,16. Recently, 
electroporation and sonoporation have been used together, in a technique logically termed 
electrosonoporation17-19. And there are a multitude of other methods, including use of cationic 
polymers, high-pressure gene delivery, particle bombardment, hydroporation, magnetofection, 
laser beam gene transduction, jet injection, photochemical internalization, and nanoparticle-
facilitated transfection9, 20.  
 Each of these methods must be optimized for the cell type and species of interest. Since 
MSCs have so many applications, researchers have already optimized different transfection 
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methods for MSCs derived from a number of different organisms, and it is clear that MSCs from 
different species have different optimal transfection parameters21. Table 1 provides an overview 
of the results of a number of optimization studies for MSCs in different species. The variability 
in peak efficiency for the same methods, or even the same reagents, is a reflection of species 
differences as well as methodological differences. Generally, physical methods perform better 
than chemical methods, with chemical transfection efficiencies ranging from 0 – 35% and 
electroporation efficiencies ranging from 2 – 90%. Nucleofection (Amaxa) is simply a 
trademarked variation on electroporation that uses cell-type-specific reagents. 
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Table 1. Efficiency of Non-Viral Transfection Methods for MSCs. Presented here are results from a 
variety of previous studies that optimized one or more nonviral transfection methods for MSCs.  If a 
percentage of expressing cells was not reported, “n.r.” is listed under Peak Efficiency. Only the 
transfection efficiency resulting from the optimized set of parameters is listed under Peak Efficiency.     
Study Organism Type of 
method 
Specific method Peak Efficiency 
(%) 
Hamm et al. 22 Human Physical Nucleofection 45 
Chemical Chemical: Lipofectamine PLUS, 
DOTAP, Effectene, Superfect, BES 
0 
Haleem-Smith 
et al. 23 
Human Physical Nucleofection 90 
Aluigi et al. 24 Human Physical Nucleofection 27 
Chemical FuGene6 
DOTAP 
3.6 
5.4 
Helledie et al.25 Human Chemical Lipofectamine 2000, Lipofectin, 
FuGene5, Lipofectamine PLUS, 
Transfectin 
15, 10, 10, 5, 5 
Physical Electroporation 90 
Madiera et al. 26 Human Chemical Lipofectamine 2000 35 
Lim et al. 27 Human Physical Microporation (a variation on 
electroporation) 
83 
Physical Electroporation 30 – 40  
Chemical  Lipofection < 20 
McMahon et al. 
28 
Rabbit Chemical Lipofectin 24 
Song et al. 29 Chick Physical Molecular vibration induced by an 
electric field (no electric current passes 
through the cell solution; transfection is 
mediated by the vibrations themselves) 
74 
Stiehler et al. 12 Pig Various Cationic liposomes, electroporation, 
magnetofection, calcium phosphate co-
precipitation 
< 2 
Gheisari et al. 
30 
Rat Chemical Effectene, FuGENE HD, Lipofectamine 
2000, Polyfect, Superfect  
8.7, 5.2, 19.6, 
16.3, 9.6 
Ferreira et al. 31 Rat Physical Electroporation 29 
Chen et al. 32 Rat Chemical Plasmid-encapsulated polyethylene 
glycolsylated polyethylenimine 
nanoparticles 
15 – 21  
Cao et al. 33 Rat Chemical Calcium phosphate nanocomposite 
particles surrounding plasmids 
n.r. (“similar to 
Lipofectamine 
2000”) 
Deng34 Rat Chemical Ethylenediamine-modified 
polysaccharide from mulberry leaves  
n.r. (“slightly 
higher than 
Lipofectamine 
2000; higher 
than PEI”) 
Santos35 Rat Chemical Receptor-mediated delivery using 
PAMAM dendrimers conjugated with 
peptides recognized by MSCs 
n.r. 
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 Surprisingly, none of these studies focus on optimizing transfection of equine MSCs. 
Equine MSCs are of interest both for their direct clinical applications to horse health, as well as 
for understanding possible human disease treatments. Horses are excellent model systems for 
study of human chondral repair, which can be mediated by use of MSCs. Not only does horse 
articular cartilage have limited healing capability, as in humans, but horses are also large enough 
to approximate lesion size found in humans—something that cannot be done in smaller models 
such as the mouse. Horses have similar knee anatomy to humans, and suffer from many of the 
same conditions, such as various cartilage injuries and osteoarthritis36. Genetically modified 
equine MSCs can be used to treat some of these conditions. For instance, MSCs engineered to 
express insulin-like growth factor-1 were used to improve healing of lesions in equine tendons37.  
Because of the many important applications of equine MSCs, and the current absence of 
studies that optimize their transfection, this study focused on discovering the best parameters for 
non-viral DNA delivery to equine MSCs.  
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Materials and Methods  
Plasmid Preparation 
Transgenic Escherichia coli carrying the pCMV-tdTomato plasmid were cultured 
overnight at 37°C in Luria-Bertani (LB) broth with kanamycin (50 mg/L). pCMV-tdTomato is a 
5392 bp plasmid that contains a CMV-driven expression cassette for the red fluorescent protein 
gene tdTomato (Clontech), as well as a kanamycin/neomycin resistance gene. Plasmid was 
purified using a commercially available plasmid preparation kit, according to the manufacturer’s 
instructions (Quiagen HiSpeed Midi/Maxi Plasmid Purification Kit, Invitrogen PureLink HiPure 
Plasmid DNA Megaprep kit).  Plasmid purity was assessed using a NanoDrop 2000 
Spectrophotometer (Thermo Scientific). pAAV-eGFP plasmid was also prepared in this manner. 
pAAV-eGFP is a 5919bp plasmid that carries an enhanced GFP expression cassette between 
inverted terminal repeats, as well as an ampicillin resistance gene, driven by a CMV promoter.  
 
MSC Isolation, Freezing, and Thawing 
All tissue culture protocols were carried out in a laminar flow hood using sterile 
techniques. MSCs were isolated from bone marrow of a healthy horse using either a 24-hour split 
method or a no-split method (Appendix 3). These isolation methods, which are based on 
differential adherence to plastic and other specific culture conditions, have been previously 
determined in this laboratory to result in purified populations of MSCs from a variety of horses. 
The cells from those horses were verified as MSCs according to their differentiation into 
adipocytes, chondrocytes, and osteocytes. Because the proper isolation procedures were followed 
here, and the procedures have been shown to produce populations of MSCs, it was reasoned that 
the cells isolated for these optimizations were MSCs.  
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After isolation, MSCs at passage 2 were suspended in MSC Freeze Media (all media 
formulations in Appendix 2) at a concentration of 5 million cells per ml. One-milliliter aliquots 
of this solution were placed in cryovials (Thermo Scientific Nalgene Cryogenic Vials, Rochester, 
NY) and gradually brought to –80°C by being placed in a Styrofoam box in a freezer overnight. 
Subsequently the cryovials were transferred to a liquid nitrogen tank for long-term storage at –
196°C (Thermo Scientific Locator 8 Cryotank).  
Upon removal from storage, the vials of MSCs were placed in a water bath at 37°C until 
thawed. The thawed cell suspensions were immediately transferred to a 50 mL centrifuge tube 
containing at least 5 mL of 10% fetal bovine serum MSC media (Appendix 2) for each cryovial, 
or at least 20 – 30 mL of media. MSCs were pelleted by centrifugation for 5 minutes at 300 x g 
in a swinging bucket rotor. The supernatant was removed from the pellet, and the cells 
resuspended in 10% or 20% FBS MSC media. After counting, cells were plated at the desired 
density on tissue culture plates (Greiner Bio-One or Corning Costar). MSCs were incubated at 
37°C, 90% relative humidity, and 5% CO2 (Thermo Scientific Forma Steri-Cult 200 CO2 
Incubator).  
 
MSC Passaging 
To passage cells, the media was aspirated from the culture vessel and the monolayer 
rinsed with Hank’s Balanced Salt Solution (HBSS) (HyClone Thermo Scientific). An appropriate 
amount of 1X trypsin EDTA was added to cover the monolayer (0.25% Trypsin/2.21 mM EDTA 
in HBSS without sodium bicarbonate, Ca, or Mg. Mediatech, Inc., Manassas, VA). MSCs were 
incubated with the trypsin for no more than five minutes, until the cells detached. The trypsin 
was quenched with MSC media and the solution transferred into 50 mL conical tubes. 
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Centrifugation at 300 x g for 5 minutes pelleted the cells, after which they were counted and 
plated at the desired density. Because MSCs begin to show changed expression of surface 
markers and unusual morphologies beyond passage 7, only MSCs at passage 5 or earlier were 
used in this study38.  
 
Fluorescence-Activated Cell Sorting: Overview 
Fluorescence-activated cell sorting (FACS) was employed to compare the expression of 
RFP and GFP by MSCs, to determine which fluorescent protein would be a better indicator of 
transfection efficiency—in other words, to determine whether MSCs express RFP or GFP more 
effectively. Additionally, this experiment was used to check whether FACS could produce a 
healthy, purified population of transfected MSCs.  
In a second FACS experiment, cell sorting was used to verify that plate reader 
fluorescence data accurately indicated the transfection efficiency. Plate readings were taken on 
populations of cells that had been transfected with varying volumes of transfection solution, so 
that each population would express the transgene to a different extent. Immediately after plate 
reading, the MSCs were sorted by FACS. The percentage of fluorescent cells in each population 
was quantified by the cell sorter. Subsequently, the relationship between the plate reader 
fluorescence reading and the percentage of fluorescent cells was determined.  
 
Fluorescence-Activated Cell Sorting: RFP vs. GFP Expression and Post-FACS Morphology 
For determining difference in expression of GFP and RFP, cryopreserved MSCs at 
passage 2 were thawed and cultured on 175 cm2 tissue culture plates (Grenier BioOne) at a 
density of 36,600 cells/cm2 in 10% FBS MSC media for 48 hours. MSCs were passaged into 75 
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cm2 plates at a density of 33,000 cells/cm2 in 18 ml of 10% FBS MSC media per plate, incubated 
for 24 hours, and then transfected with XtremeGene HD (Roche).  
Three different diluted DNA solutions (0.01 μg plasmid per μl Opti-Mem) were prepared: 
the first contained only RFP-encoding plasmid, the second contained only GFP-encoding 
plasmid, and the third contained equal concentrations of RFP-encoding plasmid and GFP-
encoding plasmid (Opti-Mem + GlutaMax Reduced Serum Medium 1X, Life Technologies). 
These DNA solutions were used to prepare transfection complexes with XtremeGene reagent 
according to the manufacturer’s protocol, with an incubation time of 15 minutes. A ratio of 1 μl 
reagent to 1 μg DNA was used, and 2800 μl of transfection solution added to each 75-cm2 plate.  
Prior to transfection the culture plates were rinsed with HBSS and 30 ml of 10% FBS 
MSC media were added to each one. The culture plates for MSCs to be transfected received 10% 
FBS antibiotic-free MSC media (Appendix 2), while all other plates received standard 10% FBS 
MSC media, which does contain antibiotics. The DNA/reagent complexes were added to the 
appropriate plates and the MSCs incubated with the transfection complexes for 48 hours. Some 
cell populations were transfected simultaneously with RFP-encoding plasmid and GFP-encoding 
plasmid, in order to have the most direct comparison possible between the two plasmids—to see 
whether a cell population presented with both plasmids in equal quantities would express one of 
the plasmids more effectively than it would express the other plasmid.  
 FACS collection tubes were coated in bovine serum albumin, to increase viability of cells 
after sorting. A solution of 4% BSA in 1X Dulbecco’s Phosphate-Buffered Saline (DPBS) was 
prepared and filter-sterilized (Cellgro Mediatech Inc., Manassas, VA). The 12 x 75 mm sterile 
polypropylene collection tubes were filled completely with 4% BSA and incubated for at least an 
hour (Fisherbrand Culture Test Tube Cat. No. 14-956-1D). Polypropylene is a useful material for 
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collection tubes since it does not accumulate charge as much as polystyrene. Prior to sorting, the 
4% BSA was poured out, and 0.5 – 1.0 ml of collection buffer was added to each tube (collection 
buffer: 50 ml fetal bovine serum, 0.5 ml Pen/Strep, 1.28 ml 1M HEPES buffer, sterile filtered).  
FACS cell samples to be sorted were prepared in a sterile hood. In the RFP vs. GFP 
expression comparison test, the media from each plate was saved before the MSCs were 
detached using trypsin. The trypsin on each plate was then quenched using the media that had 
been saved from that plate. Cells were pelleted by centrifugation at 300 x g for 5 minutes. The 
supernatant was aspirated off and cells were resuspended in PBS (Mg/Ca++ free) for counting. 
Use of Mg/Ca++ free PBS helps prevent cells from adhering to each other, and facilitates 
sorting. After counting using a hemocytometer, the MSCs were re-pelleted by centrifugation, and 
then suspended in FACS Sorting Buffer at a concentration of 107 cells/ml (FACS Sorting Buffer 
without DAPI: Appendix 2). Finally, the concentrated cell solutions were filtered through the 
caps of BD Falcon Cell-Strainer Cap 12 x 75 mm tubes (REF 352235) to reduce clumping. Prior 
to sorting the cell solutions were vortexed periodically, also to minimize clumping.  
Samples were sorted on a FACS Aria (BD Biosciences). Dead cells were excluded on the 
basis of side scatter properties. After sorting, cells were plated at high density into wells of an 
appropriate size for the cell population, and observed at 0, 16, and 48 hours. At 48 hours, the 
growth media was removed and cells covered in DPBS for imaging. Cells were photographed 
using a Cooke SensiCam High Performance Camera (Germany) and Zeiss Axiovert S100 phase-
contrast and fluorescence microscope. Subsequently only the sorted purified RFP population and 
non-sorted RFP population continued to be cultured. These cells were photographed again at 96 
hours and then discarded.   
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FACS: Plate Reading Relationship to Percentage of Fluorescent Cells  
In order to determine whether the plate reader output was actually an indicator of the 
percentage of fluorescent cells, MSCs were cultured in 96-well plates, and each plate was 
transfected with a different transfection solution volume so that different plates would have 
different percentages of fluorescent cells. The plates were analyzed with the plate reader, and 
subsequently analyzed by FACS, which provided the percentage of fluorescent cells. Then the 
plate reader output was directly compared to the transfection percentage.  
MSCs were removed from cryopreservation, cultured for 48 hours on T-175s in 30 ml of 
20% FBS MSC media per plate, and then passaged onto 96-well plates with 18,000 cells in 100 
ul of 10% FBS MSC media per well. Twenty-four hours later, the media was removed, each well 
washed with HBSS, and 100 ul of 10% FBS antibiotic-free MSC media were added to each well. 
RFP plasmid DNA was diluted in Opti-Mem to 1 ug/100 ul, and XtremeGene transfection 
complexes were prepared according to the manufacturer's instructions, in a 1:2 ratio of 
microliters XtremeGene to micrograms DNA. Each plate was treated with a specific volume of 
transfection complex solution per well: 0 μl, 16 μl, 24 μl, 28 μl, or 32 μl. Different volumes were 
used in order to obtain different percentages of cells expressing the gene.  
After 48 hours the media and transfection complexes were removed, the wells rinsed with 
1X DPBS to remove traces of media, and 100 ul of 1X DPBS added to each well. It was 
important that all media be removed because the fluorescence of phenol red occurs in the same 
range as the fluorescence of RFP. The plates were read using a Tecan Safire Plate Reader 
(Austria) with Magellan V3.11 software. Subsequently, the MSCs from each plate were 
transferred into a corresponding centrifuge tube and pelleted. Due to the small size of the pellets, 
the MSCs were not counted, but rather each pellet resuspended immediately in FACS Sorting 
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Buffer (FACS Sorting Buffer with DAPI: Appendix 2). Samples were analyzed on a FACS Aria 
(BD Biosciences). Dead cells were excluded according to the degree of DAPI fluorescence.  
 
Chemical Transfection: Overview 
Three commercially available transfection reagents were tested: XtremeGene HP 
(Roche), FuGene HD (Promega), and Lipofectamine LTX with PLUS reagent (Invitrogen). Each 
reagent can be used with varying reagent-to-DNA ratios, and with varying volumes of 
transfection complex added to the media. These two parameters, ratio and volume, must be 
optimized to attain the highest possible transfection efficiency. Because of the relationship 
between ratio and volume—i.e. solutions with higher reagent-to-DNA ratios often have more 
effective transfections at lower volumes—it is imperative that each ratio be examined across all 
volumes, rather than attempting to optimize ratio for one arbitrarily-chosen volume or optimize 
volume for an arbitrarily-chosen ratio.  
Once a reasonable range of values for ratios and volumes is determined, through an initial 
wide screen across all ratios and volumes, this range can be narrowed by further testing with 
more replicates of only the top ratios and volumes. This general approach was used to optimize 
chemical transfection: after Optimization I, in which all ratio/volume combinations for all 
reagents were screened, Optimization II was performed, in which only the top ratio/volume 
combinations for each reagent were examined in higher detail.  
 There are a number of options for quantifying transfection efficiency. Initially, Taqman-
RT PCR on RNA was used, but this was not efficient for screening many ratio/volume 
combinations. Hence, a more high-throughput method was developed, to enable accurate and 
rapid evaluation of transfection efficiency. Cells were transfected with an RFP-encoding 
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plasmid, and the resulting fluorescence of the cell population quantified by a plate reader—an 
approach that was suggested and validated by the initial FACS experiments.  The details of the 
protocol, including what range of ratios/volumes to test, how to calibrate the plate reader, the 
importance of avoiding aspiration, the timing of the transfection process, and so on, were 
determined through many earlier experiments that are not explicitly described here. Only the 
final protocol that was ultimately used to optimize chemical transfection is discussed.  
 
Chemical Transfection Optimizations I & II: Optimization of Reagent, Ratio, and Volume 
Chemical Transfection: Optimization I 
This initial optimization screened both XtremeGene and FuGene across all reasonable 
volumes across all reasonable ratios, such that peak fluorescence readings within ratios and 
across ratios could be measured. Due to the high number of unique condition sets being tested, 
each set of conditions was used on three wells.  
Cryopreserved MSCs were thawed and cultured. Cells at passage 4 were plated onto 96-
well plates at 18,000 cells per well, with 100 μl of 10% FBS MSC media in each well. After 24 
hours, the cells were put into antibiotic-free media (100 μl/well) and treated with the appropriate 
transfection conditions. FuGene reagent-to-DNA ratios of 3:2, 4:2, 5:2, 6:2, 7:2, and 8:2 were 
each tested at the following transfection solution volumes: 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 
22.5, 25, 27.5, and 30 μl added per well. XtremeGene reagent-to-DNA ratios of 1:4, 1:2, 1:1, 2:1, 
3:1, and 4:1 were each tested at the following transfection solution volumes: 2, 4, 8, 12, 16, 20, 
24, 28, 32, 36, 40, and 44 μl added per well. Each unique FuGene or XtremeGene ratio/volume 
combination was tested on three wells. Lipofectamine LTX & PLUS reagent-to-DNA ratios of 
1:1, 2:1, 3:1, 4:1, 5:1, and 6:1 were tested at 10, 20, 30, and 40 μl of transfection solution added 
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per well, with each unique ratio/volume combination tested on 18 wells. Each plate also included 
cells-only, reagent-only, and DNA-only controls.  
The transfection solutions were prepared according to the manufacturers’ instructions, 
with one difference. The manufacturers recommend adjusting the initial amount of media in each 
well so that the final volume will be 100 μl after the transfection solution has been added. 
However, instead of doing this, each well received 100 μl of 10% FBS antibiotic-free MSC 
media initially, to which the transfection solution was then added. Also, extra care was taken to 
pipette the reagent directly into the DNA solution without contacting the sides of the tube; this 
minimizes the amount of reagent that adheres to the tube instead of interacting with the DNA. In 
preparing the FuGene transfection solution, the DNA concentration was 2 μg of DNA per 100 μl 
of Opti-Mem media, to which the reagent was added. For XtremeGene and Lipofectamine LTX, 
the DNA concentration was 1 μg of DNA per 100 μl of Opti-Mem media, to which the reagent 
was added.  
After the appropriate incubation times (15 minutes for XtremeGene and FuGene; 10 
minutes after adding PLUS and 30 after adding Lipofectamine), during which transfection 
complexes assemble, each unique reagent/ratio/volume combination was applied to the 
appropriate wells. The manufacturer warns that excessive transfection complex incubation time 
can adversely affect transfection efficiency, so the layout of the 96-well plates was carefully 
designed, and the timing at which the reagent added to the DNA solution was controlled, so as to 
not exceed the recommended incubation time.  
 After 48 hours, during which the MSCs were incubated with the transfection complexes, 
the media was aspirated off and plates rinsed with HBSS. One-hundred μl of DPBS were added 
to each well, and the plate covered by a transparent sticker. The plate reader was used to quantify 
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the fluorescence in each well, with nine different reads taken in a 3 x 3 square at the bottom of 
each well. The gain was not optimized for each plate, because that would prevent a fair 
comparison between different plates. Essentially, optimizing the gain means that a different 
charge is imparted to components of the plate reader apparatus so as to provide the maximum 
spread of the data for that plate. Optimizing the gain for each plate individually would result in 
setting a different baseline for each plate. Therefore a fixed gain setting of 150 was used across 
all plates, so that fluorescence readings of different plates could be accurately compared. This 
setting, determined through previous experiments, allowed for a useful spread of the data on each 
plate. For the Lipofectamine LTX reagent optimization, the gain setting was 100, as it was part 
of an earlier experiment.   
 
Chemical Transfection: Optimization II 
 After the initial optimization, a refined optimization was performed, in which the top 
ratio/volume conditions indicated by Optimization I were re-tested on more replicates. This was 
done in order to get a clearer view of which ratio/volume conditions were the most effective.  
Cryopreserved MSCs were thawed, and cultured in 10% FBS MSC media for 48 hours. They 
were then plated onto 96-well plates at a low density of 8,000 cells in 100 μl of 10% FBS 
antibiotic-free MSC media per well. Use of antibiotic-free media at this stage meant that it was 
not necessary to change the media immediately prior to transfection, eliminating the risk of 
removal of some cells by aspiration. Cells were transfected 24 hours after being transferred to the 
96-well plates. The transfection solutions were prepared in the same manner as before. 
Ratio/volume combinations tested in this optimization are shown in Table 2.  
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Table 2. XtremeGene and FuGene Ratio and Volume Combinations Tested in 
Optimization II. The volumes for each particular ratio were carefully selected based on the 
results of Optimization I. Each unique reagent/ratio/volume combination in the table below was 
tested on multiple different wells.  
Reagent 
Ratio 
(μl reagent to 
μg DNA) 
Volumes 
(μl per well) 
XtremeGene HP 
1:2 24, 28, 32, 36 
1:1 28, 32, 36, 40 
2:1 20, 24, 28, 32 
3:1 4, 8, 12, 16 
FuGene HD 
3:2 22.5, 25, 27.5 
4:2 20, 22.5, 25 
5:2 20, 22.5, 25 
6:2 20, 22.5, 25 
7:2 12.5, 15, 17.5 
8:2 17.5, 20, 22.5 
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Each plate also contained cells-only, DNA-only, and reagent-only controls, in addition to 
wells that were transfected using a specific set of parameters for the opposite transfection 
reagent. Each XtremeGene ratio/volume combination was tested on 11 wells, and each FuGene 
ratio/volume combination was tested on 8 wells. The MSCs were incubated for 48 hours after 
transfection, before the plates were analyzed.  
 The preparation for plate reading was also slightly different than in the previous 
experiment. Instead of aspirating to remove media, which removes some cells, the media was 
simply tapped out. Then the wells were rinsed with DPBS, instead of HBSS. DPBS does not 
contain phenol red, so rinsing with DPBS has the additional benefit of not only helping to 
remove dead cells but also to remove traces of phenol red, which has similar fluorescence 
properties to RFP. Like the media, the DPBS rinse was removed by tapping, not aspiration. 
Finally, 100 μl of DPBS were added to each well and the plates were read with the same settings 
as before.  
 
Chemical Transfection: Density Optimization 
The density of cells at the time of transfection plays an important role in the efficacy of 
the transfection. Generally, lower densities lead to higher chemical transfection rates, because 
cell division facilitates the movement of introduced plasmid DNA into the nucleus. To determine 
optimal density, MSCs were plated at different densities and then transfected with the same 
reagent/ratio/volume conditions, so that any variation in the transfection efficiency would be a 
result of density alone. 
Cryopreserved MSCs were thawed, cultured for 48 hours, and then plated onto 96-well 
plates at the following densities: 8, 10, 12, 14, 16, 18, 20, and 22 x 103 cells per well. Each 
21 
 
density was used on 24 wells. After growing for 24 hours, the cells were transfected with RFP 
plasmids using an XtremeGene 1:2 ratio with 32 μl of transfection solution added per well, 
following the transfection protocol described previously. After 48 hours, the media was tapped 
out, wells rinsed with DBPS, and then filled with 100 μl of a DAPI/DPBS solution (2 μg 
DAPI/ml DPBS). DAPI was used to quantify the relative numbers of cells in each well, so that 
RFP fluorescence relative to total number of cells could be used as a comparison between 
different densities. Each well was read at 16 different locations in a 4x4 configuration.  
 
Chemical Transfection: Determining Transfection Percent 
 In order to quantify the actual percentage of cells that were transfected under certain 
conditions, MSCs were transfected, photographed, and the number of transfected and un-
transfected cells counted manually. Two XtremeGene ratios were used, and each ratio was used 
with two different plating densities, to obtain a range of transfection efficiencies.  
MSCs at passage 3 were plated onto 6-well plates at two low densities: 237,000 cells/well 
and 356,000 cells/well, in 3 ml of MSC media. After 24 hours they were rinsed with HBSS, and 
3 ml of 10% FBS antibiotic-free MSC media added to each well. Cells were then transfected 
with RFP plasmids using two XtremeGene ratios, 1:2 and 3:1, according to the transfection 
protocol described previously. Forty-eight hours later they were rinsed with DPBS, analyzed 
using the plate reader, and incubated in 4% PFA for 30 minutes. After fixation, the PFA solution 
was removed and DPBS added to each well. Plates were stored at 4°C and then photographed 
using phase-contrast and fluorescence microscopy. Fluorescent and total cell numbers were 
obtained by counting from the photographs.  
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Chemical Transfection: Effect of Ultrasonication 
 Ultrasonication has been used as a transfection method, and is sometimes employed in 
conjunction with electroporation17, 18. It is thought that the ultrasonic waves disrupt the cell 
membrane and allow DNA to enter the cell. There are no reports of ultrasonication being used 
with chemical transfection reagents, but it was hypothesized that perhaps exposure to ultrasound 
could increase the ability of chemical transfection complexes to enter the cell, thereby increasing 
the efficiency chemical transfection. Hence, chemically-transfected populations of MSCs were 
exposed to ultrasound for varying periods of time, to determine if this would alter the chemical 
transfection results.  
MSCs at passage 3 were plated onto 12-well plates at a density of 180,000 cells in 1.5 ml 
of 10% FBS MSC media per well. After 24 hours they were transfected with RFP plasmids using 
an XtremeGene 1:2 ratio, prepared according to the protocol described previously. Three wells 
per plate were treated with the following four conditions: DNA, reagent, transfection solution, or 
no treatment. Each transfected well received 380 μl of transfection solution. Subsequently, an 
Ultrasonic Instrument Cleaner (Branson Model 1210, Danbury, CT) was filled with 37°C water 
and degassed for 5 minutes.  Sets of two plates were placed inside double Ziploc bags and 
floated on the surface of the water. One set of two plates was used for each of the following 
treatment lengths: 0, 2, 4, 10, or 25 minutes of 47 kHz ultrasound. After 48 hours the plate reader 
was used to quantify fluorescence in each well. 
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Physical Transfection: Electroporation 
 Buffer, voltage, wave shape, cuvette size, number of pulses, time between pulses, cell 
density, and DNA density are a few of the parameters that can be altered to optimize 
electroporation. Promising settings for the parameters were obtained through a literature search, 
particularly from Helledie’s and Markar’s electroporation recommendations25, 39. These 
promising settings were tested in Electroporation Trial 1.  
Based on an analysis of the results of Trial 1, another set of parameters were tested in 
Trial 2, to more thoroughly examine the range of parameters that appeared most effective.  
Likewise, based on the results of Trial 2, an even narrower range of settings was tested in Trial 3, 
to determine the precise voltage that would result in the highest fluorescence. Additionally, in 
Trial 3, it was hypothesized that saving the foam that forms in the cuvette after electroporation 
might result in saving more fluorescent cells. To determine if that was true, the foam in Trial 3 
was saved and placed into specific wells that also received the standard amount of electroporated 
cell solution.  
To directly compare the efficacy of electroporation with the efficacy of chemical 
transfection, plates in Trial 3 were arranged so that half the wells contained electroporated cells 
and the other half contained cells that were chemically transfected, using one of the top three 
chemical transfection conditions (as determined through the chemical transfection optimization 
experiments.)  Thus, a plate reader analysis of each plate allowed the fluorescence of 
electroporated cells to be compared directly with the fluorescence of optimally chemically-
transfected cells. Finally, some of the populations of cells from Trial 3 were photographed and 
counted manually, to determine the transfection percentages for the optimal electroporation 
condition.   
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In all electroporation trials, MSCs were removed from cryopreservation, cultured, 
detached with trypsin, pelleted through centrifugation for 5 minutes at 300 x g, and resuspended 
in Opti-Mem for counting. Subsequently the MSCs were pelleted a second time, and 
resuspended in Opti-Mem at a density of 5 million cells/ml. RFP plasmid was added to the cell 
solution such that the final DNA concentration was 50 μg/ml. Each 2 mm electroporation cuvette 
was filled to its maximum volume of 400 μl of the plasmid/cell solution (VWR Electroporation 
Cuvettes Sterile 2mm North American Cat No 89047-208, West Chester, PA). The MSCs were 
then electroporated with a square wave, using a BTX Harvard Apparatus ECM 830 Electro 
Square Porator (Holliston, Massachusetts). The electroporation conditions used in Trials 1, 2, 
and 3 are given in Table 3. 
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Table 3. Electroporation Conditions Tested in Trials 1, 2, and 3. The Replicates column 
indicates the number of separate cuvettes that were treated with the corresponding conditions. 
Conditions tested in Trial 2 are based on results of Trial 1; likewise, conditions tested in Trial 3 
are based on results of Trial 2. Asterisks following a Group letter indicate that those conditions 
were also used on cuvettes containing only cells (as controls). The number of asterisks 
corresponds to the number of control cuvettes that were treated with those conditions. Cell 
solution from one cuvette was put into three wells of a six-well plate, or six wells of a twelve-
well plate. 
Trial 
Number 
Group Replicates 
Electroporation Conditions 
Volts 
Time of 
pulse 
No. of 
pulses 
Interval 
between 
pulses 
(msec) 
1 
 
W*** 3 130 30 msec 1 n/a 
X*** 3 130 30 msec 4 100 
Y 2 505 10 μsec 5 100 
Z 2 50 1 msec 10 100 
2 
 
K* 3 100 30 msec 1 n/a 
L* 3 130 30 msec 1 n/a 
M* 3 160 30 msec 1 n/a 
N* 3 190 30 msec 1 n/a 
3 
 
A 3 150 30 msec 1 n/a 
B** 3 160 30 msec 1 n/a 
C  3 170 30 msec 1 n/a 
D 3 180 30 msec 1 n/a 
E 3 190 30 msec 1 n/a 
F 3 200 30 msec 1 n/a 
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Cells were given a resting period of at least 10 minutes after electroporation before they 
were plated for culturing. In Trial 1, MSCs were plated in six-well plates at a density of 670,000 
cells in 3 ml of 20% FBS MSC media per well. Control wells contained untreated cells, cells 
cultured in the presence of the plasmid, and cells that were electroporated without any plasmid. 
Plates were incubated for 24 hours before being observed using phase-contrast and fluorescence 
microscopy. Then the media was replaced with DPBS and the fluorescence quantified by the 
plate reader. Each well was read 81 times, in a 9x9 square. Following observation and analysis, 
the MSCs were incubated for another 24 hours in 10% FBS MSC media, before a second plate 
reader analysis was obtained.  
In Trials 2 and 3, the MSCs were plated onto 12-well plates, at a density of 334,000 cells 
in 1.5 ml of 10% FBS MSC media per well. Electroporation causes formation of white foam in 
the cuvette. In Trial 3, this foam was specifically placed in a designated well along with that 
well’s allotment of electroporated cell solution, to determine if saving the foam resulted in higher 
fluorescence for that well. Also, one well on each plate received approximately 30 μl of extra 
electroporated cell solution, to determine if receiving extra cell solution would result in 
significantly higher fluorescence. After 24 hours, the media was tapped out, wells rinsed with 
DPBS, and then 1 ml of DPBS added to each well for plate reading. Each well was read 36 times 
in a 6x6 configuration in Trial 2, and 100 times in a 10x10 configuration in Trial 3.  
In Trial 3, twelve wells corresponding to two cuvettes that had been electroporated at 170 
volts were additionally photographed at two different locations in the well, with  both phase-
contrast and fluorescence microscopy. Subsequently, cells were counted from the photographs to 
obtain an estimate of the percentage of transfected cells. A low count and high count were 
obtained for the number of fluorescent cells. The low count was more subjective, in that it only 
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included the “brightest” cells; the high count simply included all visible fluorescent cells, 
regardless of brightness level. Additionally, an electroporation Trial 4 was performed, in which 
the cells were electroporated with the same conditions used in Trial 2, except that the 
electroporation buffer was 20% FBS MSC media instead of Opti-Mem. Trial 4 was carried out to 
determine whether culture medium could be a satisfactory electroporation buffer.  
As part of Trial 3, electroporation was directly compared with the best XtremeGene 
transfection conditions. Cryopreserved MSCs to be chemically transfected were thawed and 
cultured at a density of 34,000 cells/cm2 in 20% FBS MSC media. After 48 hours they were 
passaged into 12-well plates at a density of 25,000 cells/cm2, and cultured in 10% FBS 
antibiotic-free MSC media. Cells were only placed in six of the wells of each 12-well plate, and 
the other six wells left empty. After 24 hours, the media was removed and each well received 1.5 
ml of new 10% FBS antibiotic-free MSC media immediately prior to transfection.  
XtremeGene transfection solutions of 3:1. 2:1, and 1:1 ratios were prepared according to 
the manufacturer’s instructions. Each particular XtremeGene ratio was used on the six wells 
containing cells, with the other six wells left empty. MSCs transfected with the 3:1 ratio received 
143 μl of transfection solution per well, those transfected with the 2:1 ratio received 238 μl of 
transfection solution, and those transfected with the 1:1 ratio received 380 μl of transfection 
solution, corresponding to the optimal volumes for those ratios as determined previously, but 
scaled up for larger wells. One plate was left untransfected. Following transfection, the cells 
were cultured for 24 hours. 
After 24 hours, electroporated cells were added to the six empty wells of each 12-well 
plate. These electroporated cells had been thawed 48 hours previously and cultured in 20% FBS 
MSC media at a density of 34,000 cells/cm2. They were electroporated using the protocol 
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described previously, with parameters set to one 30-msec, 160-volt pulse per 2-mm cuvette. Each 
cuvette was used to seed five of six empty wells with transfected cells. In the remaining empty 
well of each plate were placed control non-electroporated cells at the same density as the wells 
receiving electroporated cells, that is, 335,000 cells per well. Plates were placed in the incubator 
for 24 more hours before analysis. Thus, the electroporated cells had 24 hours after transfection 
before they were analyzed, and the chemically-transfected cells had 48 hours after transfection 
before they were analyzed.  
For analysis, media was removed and wells rinsed with DPBS. One ml of DPBS was 
added to each well and the plate reader used to quantify fluorescence levels. One hundred reads 
were taken on each well, in a 10x10 square. After plate reading, each well was photographed in 
two locations using phase-contrast and fluorescence microscopy.   
 
Statistical Analysis 
All statistical analysis was performed using R, A Language and Environment for 
Statistical Computing (R Foundation for Statistical Computing, Vienna, Austria), with the 
exception of regression, which was done using Microsoft Excel. Data were compared and 
analyzed using ANOVA (with Tukey Highly Significant Differences post-hoc testing), the 
Wilcoxon Rank Sum test, the Wilcoxon Signed Rank test, or Welch’s two sample t-test, 
depending on sample size and distribution of the data.  
Normal quantile-quantile plots were used to determine if data was normally-distributed. 
If the data were not normally-distributed, they were analyzed using a non-parametric test. The 
powerful Wilcoxon non-parametric tests can be applied to large, normal datasets, but are 
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especially useful for smaller sample sizes or non-normal datasets. Note that the p-values reported 
are often less than 2.2e-16, since R does not report p-values any smaller than this.  
In the density optimization, comparing the raw RFP fluorescence readings of the different 
densities would not indicate which density had the highest transfection percentage, simply 
because higher densities have more possible cells that can be fluorescent, so a lower efficiency in 
a high density could produce a higher RFP reading than a higher efficiency in a lower density. 
Therefore, the raw RFP values were scaled according to the DAPI reading for that well, and the 
RFP/DAPI ratio of different densities were statistically analyzed.   
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Results 
FACS: RFP vs. GFP Expression and Post-FACS Morphology 
 This FACS sorting was carried out to determine which fluorescent protein would be a 
better reporter gene—more specifically, whether GFP or RFP would be more readily expressed 
and thus a better indicator of transfection efficiency. RFP-encoding plasmid and GFP-encoding 
plasmid were co-transfected to determine whether a cell population presented with both plasmids 
would express one of the plasmids more readily than the other. Overall, more MSCs expressed 
RFP than GFP. Out of the total cell population that was transfected simultaneously with RFP 
plasmid and GFP plasmid, 18.3% expressed RFP only, 2.1% expressed GFP only, and 3.3% 
expressed both GFP and RFP. The overall percentage of transfected cells was 23.7%, determined 
by summing the aforementioned percentages. This percentage is for an Xtreme 1:1 ratio.  
An additional purpose of the FACS test was to determine whether a substantial, healthy 
population of purified, transfected MSCs could be obtained through fluorescence-activated cell 
sorting. Only small cell populations of fluorescent cells were obtained, and the morphology of 
the sorted cells that were actually expressing a transgene was particularly unusual, as shown in 
Figure 1 (compare Photos 1a – 1d, of expressing, sorted cells, with the remaining Photos.) In 
general, the cells with the most unusual morphology were the sorted, expressing cells (Photos 1a 
– 1d), followed by the cells that were transfected but unsorted (Photos 2a, 2b, 3a, and 3b), and 
finally, the most normal cells were the sorted, un-expressing cells (Photo 1e), and naturally, the 
unsorted, untransfected control (Photo 4). 
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Figure 1. Phase-Contrast and Fluorescence Photographs of Expressing/Non-expressing, 
and Sorted/Unsorted Cells.  
“Double” indicates that the cells came from the population that was transfected with both RFP 
and GFP plasmid simultaneously, which was done in order to compare GFP and RFP expression 
within the same cell population. “Single” indicates that the cells came from a population 
transfected with only RFP or only GFP. The “single” cells, which were transfected but not 
sorted, are a transfection morphology control—these unsorted, expressing cells can be compared 
with the sorted, expressing cells to determine if there are morphological differences due to 
sorting. Unsorted, non-expressing cells can also be compared with sorted, non-expressing cells to 
help determine if there are morphological differences due to sorting. The singly-transfected cell 
populations were also useful for determining whether RFP or GFP was expressed more 
effectively. Some cells were neither transfected nor sorted, as a general control. The leftmost 
column of the table indicates whether the cells were sorted, and what gene(s) they are 
expressing. Because there were almost no “Double: Sorted: GFP-only” cells after 48 hours, 
photographs for those cells are not included. Cells were photographed 48 hours after their 
sorting. Cells that had not been sorted were also photographed at this same time.  
 
Condition Fluorescence Phase Contrast 
Double: 
Sorted: 
Expressing 
RFP only  
  
Double: 
Sorted:  
Expressing 
RFP and 
GFP  
  
1a 1b 
1c 1d 
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Double: 
Sorted:  
Not 
expressing 
either 
transgene 
(no RFP,  
no GFP) 
 
 
 
 
Fluorescence photo N/A 
 
Single: 
Un-Sorted: 
RFP-only 
  
Single: 
Un-Sorted: 
GFP-only 
  
Control:  
Unsorted, 
Not 
transfected 
 
 
 
2a 2b 
3a 3b
\\ 
4 
1e 
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FACS: Plate Reading Relationship to Percentage of Fluorescent Cells 
This second FACS sorting was conducted on cell populations that had been transfected 
with varying degrees of efficiency, and was used to determine if there was a relationship between 
the plate reader fluorescence reading and the actual percentage of fluorescent cells in the 
population. Cells were analyzed with a plate reader and subsequently sorted on a FACS Aria. 
The percentage of fluorescent cells in the population was provided by the cell sorter after sorting.  
There was a strong linear relationship between the average plate reader fluorescence 
reading for a plate, and the percentage of fluorescent cells for that plate, which is shown in 
Figure 2 (R2 = 0.98). Each point on the graph corresponds to the next-highest transfection 
solution volume used; the different transfection solution volumes did lead to significant 
differences in fluorescence levels, depicted in Figure 3 (ANOVA, followed by Tukey-Kramer 
HSD Test, p < 0.0001) for every pairwise comparison of volumes except for the last two, 28 μl 
vs. 32 μl.  
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Figure 2. Percentage of Fluorescent Cells vs. Plate Reader Fluorescence Reading.  
Fluorescence readings from the plate reader are strongly correlated with percentage of 
fluorescent cells as determined by FACS. Higher plate reader readings correspond to higher 
percentages of fluorescent cells. The percentage of transfected cells is not particularly high here 
because this experiment was carried out before any of the transfection protocols had been 
optimized. Also, the plate reader gain setting used here was slightly different from the gain 
setting used in some other experiments—which, though it changes nothing about the plate 
reader’s efficacy as an instrument and only alters the absolute numerical value of the output, 
means that the numerical fluorescence readings in other experiments should not be translated 
into a transfection percentage using this graph.  
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Figure 3. Distribution of Fluorescence Readings for Wells of 96-Well Plates Transfected by 
Different Volumes of XtremeGene 1:2 Transfection Solution. Each individual well reading is 
represented by a single black dot. Each transfection solution volume was used on 96 wells, so 
there are 96 black dots for each volume.  
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Chemical Transfection Optimizations I & II: Optimization of Reagent, Ratio, and Volume 
Chemical Transfection: Optimization I 
 The initial optimization across all reagents, ratios, and volumes, indicated that some sets 
of conditions resulted in higher fluorescence than others. A comparison of all fluorescence 
readings of each reagent/ratio combination indicates that three pairs of FuGene ratios 
significantly differed from each other (Wilcoxon Rank Sum, 3:2 vs. 8:2, and 4:2 vs. 8:2, p < 
0.05) while six pairs of XtremeGene ratios significantly differed from each other (Wilcoxon 
Rank Sum, 1:4 vs. 2:1, 3:1, 4:1, and 1:1 vs. 2:1, 3:1, 4:1; p < 0.03). However, when FuGene 
ratios were compared to XtremeGene ratios, there were 22 significantly different pairings out of 
36 total pairings (Wilcoxon Rank Sum, p < 7.53e-05 for 18/22 pairwise comparisons, and p < 
0.03 for all 22 of the pairwise comparisons). XtremeGene overall has higher fluorescence 
readings than FuGene overall (Wilcoxon Rank Sum, p = 9.89e-7). Additionally, XtremeGene 
and FuGene each had significantly higher fluorescence readings than the controls (Wilcoxon 
Rank Sum, p < 2.2e-16).    
 The FuGene ratios all tended to have peak fluorescence around a transfection solution 
plating volume of 22.5 μl per well, as indicated in Figure 4. However, the XtremeGene ratios 
each had different volumes at which fluorescence was maximal, appearing to follow a third-order 
polynomial (R2 = 0.95) and with higher ratios showing lower most effective volumes, as shown 
in Figures 4 and 5. Lipofectamine LTX had peak fluorescence at a 4:1 ratio, 10 μl plating volume 
(Appendix 1, Table S1).  
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Figure 4. Chemical Transfection Optimization I: Trends in Fluorescence Readings Across 
All Ratios and Volumes for FuGene and XtremeGene Reagents.  
The number provided for each ratio is the microliters of reagent that correspond to one 
microgram of DNA, which is why the XtremeGene 1:4 ratio is listed as 0.25 and the 1:2 ratio as 
0.5. Notice the difference in scale on the y-axis of the two graphs; XtremeGene clearly results in 
higher fluorescence levels than FuGene. 
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Figure 5. Volume At Which Maximum Fluorescence Occurred Across Six XtremeGene 
Ratios. For each ratio, the volume at which the highest fluorescence reading was achieved is 
plotted against the ratio. Lower ratios have generally higher optimal plating volumes. 
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Chemical Transfection: Optimization II 
 This experiment focused on the transfection conditions that resulted in the highest 
fluorescence readings in Optimization I, and evaluated these conditions with more replicates. 
XtremeGene ratios of 1:2, 1:1, 2:1, and 3:1 were tested for the top four volumes in each ratio; 
FuGene ratios of 3:2 to 8:2 were tested for the top three volumes in each ratio.  
FuGene and XtremeGene again both had significantly greater fluorescence than controls, 
and, as apparent in Figure 6, XtremeGene had significantly greater fluorescence than FuGene 
(Wilcoxon Rank Sum, p < 2.2e-16). Within XtremeGene, each ratio was significantly different 
from each other ratio (Wilcoxon Rank Sum, p < 0.0001), with the exception of the 2:1 ratio 
against the 1:1 ratio. Pooling the 2:1 and 1:1 XtremeGene data and comparing it with the other 
XtremeGene data showed that the fluorescence readings of 2:1 and 1:1 ratios were higher than 
the readings of the 3:1 and 1:2 ratios (Wilcoxon Rank Sum test, p < 2.2e-16). For the 2:1 and 1:1 
ratios, the only volumes that had significantly different fluorescence readings from any others 
were the 2:1 ratio 20 μl volume, the 2:1 ratio 32 μl volume, and the 1:1 ratio 32 μl volume 
(Wilcoxon Rank Sum, p <  0.029).  
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Figure 6. Chemical Transfection II, FuGene and XtremeGene Average Fluorescence 
Readings for Top Ratio/Volume Combinations. The second chemical transfection 
optimization tested the top four volumes of each of the top four ratios for XtremeGene, and the 
top three volumes of each of the six ratios for FuGene. The average fluorescence reading for 
each ratio/volume combination is depicted below.  
XtremeGene treatments are shown in green, and FuGene treatments are shown in blue. The 
alternating light and dark colors within each ratio emphasize the grouping by ratio. Ratios 
increase from left to right within a reagent, and volume increases from left to right within a ratio. 
XtremeGene ratios are written as the μl of reagent that would correspond to 1 μg of DNA (hence, 
0.5 refers to the 0.5:1 ratio, which is elsewhere referred to as the 1:2, ratio), while FuGene ratios 
are written as the μl of reagent that would correspond to 2 μg of DNA. Volumes are provided as 
μl added per well of a 96-well plate, where each well initially contains 100 μl of media.  
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Chemical Transfection: Density Optimization  
This experiment was performed to determine the effect of cell density on chemical 
transfection efficiency. MSCs were plated across a wide range of densities, and these separate 
populations transfected with the same set of conditions, to see how the density would impact the 
percentage of fluorescent cells obtained.  
In this experiment it was important to compare the relative RFP/DAPI ratios rather than 
the raw RFP readings, because the deliberate variation in total cell numbers was guaranteed to 
skew the final sizes of the populations (see Statistical Analysis in Methods, and Figure 7 below 
for more information.)  
As a check, it was determined that the wells that received more cells had higher DAPI 
fluorescence readings (linear regression, R2= 0.94). The lowest density (8 x 103 cells/well) had a 
significantly higher RFP/DAPI fluorescence ratio than the second-highest density (20 x 103 
cells/well) (Welch Two-Sample t-test, p = 0.0009). Additionally, the lowest density (8 x 103 
cells/well) had significantly higher RFP/DAPI ratio than the highest density (22 x 103 cells/well) 
(Welch Two-Sample t-test, p=0.005). Overall, the lower densities had greater RFP/DAPI ratios 
than the higher densities, a trend that can be easily seen in Figure 7. 
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Figure 7. Average RFP/DAPI Fluorescence Ratio for Transfection at Different Cell Plating 
Densities.  
Because the RFP fluorescence reading is indicative of the number of transfected cells in a well, 
and the DAPI fluorescence reading is indicative of the total number of cells, the RFP/DAPI ratio 
is related to the percentage of fluorescent cells. Note that although comparing RFP/DAPI ratios 
is useful for understanding relative transfection percentages, the actual value of the ratio itself 
does not equal the exact transfection percentage, due to the differing properties of the fluorescent 
molecules. The reason the RFP/DAPI ratio was used to analyze transfection success, rather than 
the RFP reading alone, is that the final cell populations have different sizes according to the 
differing densities. Therefore, if RFP reading alone were used, higher densities would have an 
“unfair advantage” by virtue of simply having more cells present. Here it can be seen that higher 
densities have a smaller RFP/DAPI ratio, indicating a smaller percentage of fluorescent cells 
than the lower densities.  
 
 
  
0.03
0.035
0.04
0.045
0.05
0.055
0.06
6000 8000 10000 12000 14000 16000 18000 20000 22000 24000
R
FP
/D
A
P
I 
Fl
u
o
re
sc
e
n
ce
 R
at
io
 
Density (# of cells per well of 96-well plate)
43 
 
Chemical Transfection: Determining Transfection Percent 
 Overall 16,400 cells were counted, to determine the transfection percentages for two 
densities and two transfection ratios, shown in Figure 8. The highest transfection percentage was 
24%, for the lower density XtremeGene 1:2 ratio.  
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Figure 8. Transfection Percentage for Two XtremeGene Ratios and Densities.  
The blue bar indicates a lower estimation of the transfection percentage, obtained by a count of 
only the brightest fluorescent cells. The red bar indicates the transfection percentage as 
determined when every fluorescent cell was counted, regardless of its relative brightness.   
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Chemical Transfection: Effect of Ultrasonication 
 Chemically-transfected cells were ultrasonicated for differing periods of time, to 
determine how ultrasound would affect the transfection efficiency. The fluorescence readings for 
cell-only, DNA-only, and reagent-only controls were negligible, even if the plate was 
ultrasonicated. For the chemical transfection solution treatments, wells that were ultrasonicated 
for 4 minutes had significantly higher fluorescence than non-ultrasonicated transfection wells 
(Wilcoxon Rank Sum, p=0.021). Transfection wells treated for 25 minutes had significantly 
lower fluorescence than non-ultrasonicated transfection wells (Wilcoxon Rank Sum, p=0.032). 
 
Physical Transfection: Electroporation 
Trial 1: 
This was the initial optimization, which tested a variety of conditions to determine what 
parameters merited further investigation. The X group (130 V, four 30-msec pulses), including 
both X samples and X controls, were completely dead after 24 hours. Out of the groups where 
cells did survive, the only group with fluorescent cells was group W (130 V, one 30-msec pulse). 
This group had fluorescence readings that were significantly different from the fluorescence 
readings of the non-electroporated controls (Wilcoxon Rank Sum, p=0.0002). Groups Y (505 V, 
five 10-μsec pulses) and Z (50 V, ten 1-msec pulses) did not have any fluorescent cells present.  
Trial 2: 
 Here, parameters in a range suggested by Trial 1 were tested in more detail. Groups K 
(100 V, one 30-msec pulse), L (130 V, one 30-msec pulse), M (160 V, one 30-msec pulse), and 
N (190 V, one 30-msec pulse) all had fluorescence that was significantly greater than the 
controls (Wilcoxon Rank Sum, p < 2.56e-10). All groups were significantly different from each 
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other (Wilcoxon Rank Sum on each pairwise comparison, p < 0.037). Group M (160 V) had 
significantly higher fluorescence than all other groups, as suggested by Figure 9 (Wilcoxon Rank 
Sum test, p=0.0012 for 190V, p=6.45e-09 for 100V, p=4.32e-07 for 130V). 
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Figure 9. Fluorescence Readings of Cell Populations 24 Hours After Electroporation At 
Four Different Voltages, and Photographs of Highest Fluorescence Populations.  
The peak in the graph occurs at 160 volts. Photographs were taken in Trial 2, twenty-four hours 
after electroporation. The two photographs shown are from populations electroporated at 160 
volts. 
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Trial 3:  
 This test was designed to further narrow the voltage range based on results of Trial 2; to 
determine the effect of saving the electroporation foam; and to directly compare the transfection 
efficiency of electroporation with the transfection efficiency of the optimal chemical transfection 
parameters.   
Every electroporated group had higher fluorescence than the controls (Wilcoxon Rank 
Sum, p < 5.77e-07). When fluorescence readings from different voltages were compared, the 
readings for the Group C (170 V) were significantly higher than the readings for all other 
voltages, as indicated in Figure 10 and 11 (Wilcoxon Rank Sum, p < 0.0073). Additionally, the 
readings for the Group D (180 V) were significantly higher than the readings for Groups B, E, 
and F (160, 190, and 200 V) (Wilcoxon Rank Sum, p < 0.013).  
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Figure 10. Results of Statistical Analysis Indicating that Group 170 Volts Had Higher 
Fluorescence Than All Other Voltages.  
Wilcoxon Rank Sum p-values are shown, for the alternative hypothesis that Group C (170 volts) 
has brighter fluorescence than the group noted in the leftmost column.  
Group 
(Voltage) 
Wilcoxon  
p-value 
A (150) 0.00726 
B (160) 0.000197 
D (180) 0.0064 
E (190) 1.33e-05 
F (200) 1.754e-06 
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Figure 11. Fluorescence Readings for Six Electroporation Voltages and the Top Three 
XtremeGene Transfection Ratios.  
The highest fluorescence readings were achieved by the group electroporated at 170 volts. The 
XtremeGene 2:1 and 1:1 ratios have fluorescence readings similar to those of the groups 
electroporated at 160, 190, and 200 volts.  
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Next, fluorescence readings for wells were paired according to source cuvette, and 
separated by whether the well had the standard amount of electroporated cell solution added, or 
also had cell foam or extra solution added. The wells that had received foam in addition to cell 
solution had higher fluorescence than the wells that had only received the standard amount of 
cell solution (Wilcoxon Signed Rank Test, p=0.0017). The wells that had received extra solution 
had higher fluorescence than the wells that had only received the standard amount of cell 
solution (Wilcoxon Signed Rank Test, p=3.815e-06). And, the wells that had received extra 
solution had higher fluorescence than the wells that had received foam (Wilcoxon Signed Rank 
Test, p=0.002).  
The electroporation conditions of Trial 3 for 170 volts resulted in 40.1% of cells being 
“brightly” fluorescent (2356 brightly fluorescent cells out of 5876 total cells), and 53.6% of cells 
having fluorescence (3148 fluorescent cells out of 5876 total cells). In Trial 4, when the cells 
were electroporated in 20% FBS MSC media to determine if media was a satisfactory buffer, 
visual observation indicated that almost no fluorescent cells were present whatsoever.  
 In the direct comparison of XtremeGene to electroporation transfections, both 
XtremeGene and electroporation resulted in fluorescence levels significantly higher than that of 
the controls, which included untreated cells, cells treated with naked DNA, and cells 
electroporated by one 30-msec pulse of 160 V without DNA present (Wilcoxon Rank Sum, p < 
1.02e-07). Cells transfected with the Xtreme 2:1 ratio had higher fluorescence than those 
transfected with the 3:1 ratio and those transfected with the 1:1 ratio (Wilcoxon Rank Sum, p < 
0.05).  The electroporation with 170 volts resulted in significantly greater fluorescence levels 
than any of the XtremeGene transfection ratios (Wilcoxon Rank Sum, p < 0.027). Photographs of 
cells electroporated at 170 volts are shown in Figure 12, along with chemically-transfected cells. 
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Figure 12. Fluorescence Photographs of Cells 24 Hours After Electroporation at 170 Volts, 
and 48 Hours After Chemical Transfection by XtremeGene.  
The photographs illustrate the same trend apparent from the plate reader fluorescence 
quantification—namely, that electroporation at 170 volts resulted in the most fluorescent cells, 
followed by XtremeGene ratios 2:1, 1:1, and last of all 3:1.  Additionally, it can be seen that 
chemical transfection led to rounder cell morphology, whereas a substantial proportion of the 
electroporated cells retained a more characteristic spindle shape.  
 
Electroporation at 170 V 
 
 
 
XtremeGene 3:1 
 
 
 
XtremeGene 2:1 
 
 
 
XtremeGene 1:1 
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Discussion 
Fluorescence-Activated Cell Sorting 
For a transfection reporter gene, tdTomato appears to be more effective than eGFP. When 
cells were transfected with equal amounts of both plasmids, RFP was expressed more highly, and 
when separate populations were transfected with one plasmid or the other, there were far more 
fluorescent cells in the RFP-transfected population than the GFP-transfected population. One 
reason for this disparity could be a difference in protein brightness—after all, tdTomato is 
advertised as being a particularly vibrant protein. If the RFP was brighter than the GFP, then in 
the dually-transfected population, the FACS Aria may have categorized some GFP-transfected 
cells as untransfected, and additionally could have categorized some dually-expressing cells as 
expressing only RFP. However, visual observation of cells that had been transfected with only 
RFP or only GFP also showed a dramatic difference in the proportions of cells expressing RFP 
as compared to GFP, suggesting that for whatever reason MSCs expressed tdTomato more 
effectively. Hence, the RFP plasmid was chosen as the reporter gene for the optimization 
experiments. 
In addition to suggesting the best fluorescent protein to use, the FACS results also 
provided more motivation for optimizing transfection. Fluorescence-activated cell sorting of a 
cell population transfected at medium efficiency does not appear to be the most efficient way of 
obtaining a healthy, pure population of low-passage-number equine MSCs all expressing a gene 
of interest. The population ultimately obtained is small, and cells are thoroughly stressed by the 
sorting process. In spite of coating the collection tubes with BSA and using a sorting buffer 
recipe that was designed to maximize cell survival, the morphology of the MSCs after sorting 
was unusual for a number of days after sorting. Also, undoubtedly some of the transfected cells 
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were lost in the sorting process, because cells with lower fluorescence levels might not reach the 
set cutoff point. It is more efficient to simply use an effective transfection method to begin with. 
Based on the FACS measurement of the proportion of fluorescent cells transfected by different 
volumes of XtremeGene 1:2 ratio, as well as the plate reader output for those same cell 
populations, it also became clear that transfection solution volume was one of the key parameters 
to optimize, since different volumes resulted in dramatically different transfection efficiencies.  
The FACS sorting results also suggest that expression of a transgene may have a more 
dramatic effect on cell morphology than FACS sorting itself, since the cells that were expressing 
a transgene but were not sorted had a more unusual morphology than the cells that were sorted 
but not expressing a transgene. However, FACS sorting still clearly has an effect, since the cells 
with the most unusual morphology were the ones that were both sorted and expressing a 
transgene.  
 As evidenced by the FACS/plate reader standard curve, the plate reader appears to be an 
effective way of measuring relative gene expression among different populations of cells. The 
value given by the plate reader has a strong linear relationship to the actual percentage of 
fluorescent cells present, with higher fluorescence readings indicating a proportionally higher 
percentage of expressing cells. Thus, both the use of RFP as a reporter gene and the use of the 
plate reader to quantify transfection efficiency are strongly supported by the results of the FACS 
tests. 
 One detail that is worth discussing is the plate reader’s potential inability to distinguish 
between large numbers of dim cells and high numbers of bright, tiny cells or vesicles. This 
would be a complication if the different transfection methods resulted in dramatic variation in the 
brightness or sizes of cells observed. However, it seems qualitatively that there is no substantial 
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difference in size or brightness variation between chemically-transfected cells and electroporated 
cells. Possibly, the chemically-transfected cells may be slightly rounder than electroporated cells, 
and may expel more fluorescent vesicles, probably to clear out reagents. But even with their 
“unfair advantage”—since, after all, the quantity of interest is proportion of fluorescent cells and 
not proportion of fluorescent vesicles—the chemically-transfected cells still had significantly 
lower fluorescence than the electroporated cells. Whether or not there actually is a difference in 
size or brightness of chemically-transfected cells compared to electroporated cells is not obvious, 
so there appeared to be no need to conduct a of quantitative assessment of this potential 
variation. Perhaps, if other transfection methods had been tested that resulted in sharp changes of 
size or brightness variation, the plate reader strategy would have had to be modified.  
A minor point of conflict between the data from two of the experiments is the relative 
fluorescence level of the 28 μl volume and the 32 μl volume for an XtremeGene 1:2 ratio. In 
Chemical Optimization I, use of 32 μl per well led to approximately twice the fluorescence level 
of 28 μl per well. However, when the plate reader’s accuracy was being verified through FACS, 
there was no significant difference between the fluorescence resulting from use of 32 μl and use 
of 28 μl. Most likely, this is simply a reflection of the small sample size used in Optimization I 
(n=3) against the much larger sample size used for each volume in the plate reader test (n=96), 
and was part of the motivation for conducting the second, refined chemical optimization. 
Chemical Optimization II included larger sample sizes than Optimization I. It is noteworthy that 
the general trend of increasing expression as the transfection solution volume increases from 16 
μl up to 32 μl was the same between the two tests.  
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Chemical Transfection Optimizations 
XtremeGene proved to be a better transfection reagent than FuGene HD. The most 
effective ratios for transfecting equine MSCs are the XtremeGene 2:1 and 1:1 ratios. According 
to the data from both Optimization II and the final direct comparison of XtremeGene 1:1, 2:1, 
and 3:1 ratios to electroporation, the best overall set of conditions for chemical transfection is an 
XtremeGene 2:1 ratio, with a volume added that is equivalent to 20 μl of transfection solution 
added per well of a 96-well plate, where each well initially contains 100 μl of media. To ensure 
satisfactory transfection, the XtremeGene used should be as new as possible, since it was 
discovered that expired XtremeGene does not work (Appendix 1, Table S2). It is also worth 
noting that Lipofectamine LTX & PLUS reagent could still prove more effective than 
XtremeGene; though it had promising initial results, Lipofectamine was not optimized further 
only because of delays encountered when attempting to obtain more of the reagent. 
In addition to choosing a useful reagent, ratio, and volume, it is important to use low 
density of cells, to achieve maximum chemical transfection efficiency. When compared to other 
densities, the lowest density of 8,000 cells/well had the highest RFP/DAPI fluorescence ratio, 
indicating that it had the highest percentage of cells transfected. It is possible that even lower 
densities than this could produce higher percentages of fluorescent cells, an avenue that could 
easily be explored in further experiments.  
The effects of ultrasound on chemical transfection efficiency are not clear. Although 
ultrasonication for 4 minutes did appear to increase the transfection efficiency, ultrasonication 
for 25 minutes had the opposite effect. Perhaps, 4 minutes was long enough to facilitate entry of 
transfection complexes into cells, but 25 minutes was so long that it caused permanent damage to 
cellular structures and, through killing cells, resulted in lower transfection efficiency. The 
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frequency used in this experiment, 47 kHz, is not a frequency that is typically used, nor are 
ultrasonic instrument cleaners the usual method of sonoporating cells. Checking whether other 
frequencies at other durations would increase chemical transfection efficiency would certainly be 
interesting. Additionally, use of microbubbles or other sonoporation reagents may lead to 
discovery of another highly efficient nonviral transfection method for equine MSCs. Already, the 
non-optimal XtremeGene 1:2 ratio transfection percentage of 24% is on the higher end of MSC 
chemical transfection efficiencies previously reported (Table 1).  
 
Physical Transfection: Electroporation  
Electroporation is the best transfection method out of all methods studied here. The 
optimal set of parameters for transfecting equine MSCs are concentrations of 5 million cells/ml 
and 50 μg plasmid/ml, with 1 square-wave 30-msec 170-volt pulse. It is critical that Opti-Mem 
be used as the buffer, since use of MSC media as the buffer results in very poor transfection 
efficiency. Also, saving the “foam” that forms in the cuvette results in a greater number of 
fluorescent cells. Most likely, the foam is composed of cells. The maximum equine MSC 
electroporation efficiency achieved, 54%, is on the higher end of maximum MSC electroporation 
efficiencies previously reported, which include 30-40% and 90% for humans, <2% in pig, and 
29% in rat12, 25, 31, 40.  
It would be useful to determine if electroporation or chemical transfection of equine 
MSCs affected their stem cell characteristics in any way. In a study on rats, electroporation did 
not affect MSC multidifferentiation; they were successfully differentiated down osteoblast, 
adipocyte, and chondrocyte pathways31. However, in a separate study, Lipofectamine-transfected 
human MSCs characteristics were altered by the chemical treatment25. Information about the 
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effects of transfection on MSC “stemness” could provide additional help in choosing which 
method to use. 
It would also be worthwhile to study the effects of electroporation and XtremeGene-
mediated transfection on gene expression in MSCs, since the transfection methods themselves 
can cause differential gene expression that is unrelated to the actual gene that is transferred to the 
cell. One study found greater than a tenfold change in the number of differentially expressed 
transcripts, depending on which transfection reagent they used, because transfected cells can 
react to the transgene as they would to a viral infection even when viruses themselves are not 
used for gene delivery41. Potentially, the unique ways in which gene expression is altered 
between these methods could change the therapeutic potential of the MSCs, and provide new 
insight as to which method could be better in a given situation. However, if transfection 
efficiency is the primary concern, then electroporation is the best method.  
Equine MSCs are a valuable cell type, and provide opportunities to learn more about 
horse health and, by inference, human health. These optimized transfection methods, especially 
the set of highly effective electroporation parameters, will undoubtedly be useful to the multitude 
of researchers who wish to genetically modify equine MSCs. 
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List of Abbreviations 
 AAV: Adeno-associated virus 
 BSA: Bovine serum albumin 
 CMV: cytomegalovirus  
 DAPI: 4’,6-diamidino-2-phenylindole 
 DPBS: Dulbecco’s Phosphate-Buffered Saline 
 EDTA: Ethylenediaminetetraacetic acid 
 FACS: Fluorescence-activated cell sorting 
 FBS: Fetal bovine serum 
 GFP: Green fluorescent protein 
 HBSS: Hank’s Balanced Salt Solution 
 HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
 HDS: Highly Significant Differences 
 MSC: Mesenchymal stem cell 
 PFA: paraformaldehyde  
 RFP: Red fluorescent protein (here refers to tdTomato) 
 RT-PCR: real-time polymerase chain reaction 
 
 
Conflict of Interest 
The author certifies that there are no conflicts of interest regarding the material discussed in this 
manuscript.   
60 
 
Acknowledgements 
 
 First I wish to thank my God, my parents, my grandparents, and Rebecca, Joseph, and 
Catherine, for their continuous support in my endeavors at Cornell, including all the work that 
has gone in to this thesis. Without them, this would not have been possible.  
 I am very grateful to Dr. Alan Nixon, for the excellent opportunity to work in his 
laboratory, his scientific advice, and his valuable suggestions for improving this manuscript. I 
thank the other reviewers of my thesis for their input as well. 
I would also like to thank Jeremy Ackerman-Yost and Michael Scimeca for teaching me 
countless laboratory techniques. Mike also patiently answered my endless stream of questions, 
which was immensely helpful throughout the design, execution, and write-up of this project. I 
also thank him for his feedback on this manuscript. I am indebted to everyone in the Nixon lab 
for their suggestions and good conversation, as well as to Lavanya Sayam for her explanations 
regarding FACS.  
Additionally, I thank Dr. John Hermanson, for introducing me to research when I was a 
freshman, inspiring me to keep at it, and providing much helpful advice throughout my three 
years at Cornell. I likewise thank my academic advisor and thesis group leader Dr. Ellis Loew, 
for his recommendations about undergraduate research and preparing for graduate school. My 
appreciation also extends to Colleen Kearns and Janet Snoyer, for listening, and for their cheerful 
encouragement.  
I am sincerely thankful to all these individuals and countless others who have been a 
positive influence throughout my time at Cornell.  
 
 
 
 
61 
 
References 
1. Porada, C. D., Zanjani, E. D. & Almeida-Porad, G. Adult mesenchymal stem cells: a 
pluripotent population with multiple applications. Current stem cell research & therapy 1, 365-
369 (2006). 
2. Barry, F. & Murphy, J. Mesenchymal stem cells: clinical applications and biological 
characterization. Int. J. Biochem. Cell Biol. 36, 568-584 (2004). 
3. Barry, F. & Murphy, J. Mesenchymal stem cells: clinical applications and biological 
characterization. Int. J. Biochem. Cell Biol. 36, 568-584 (2004). 
4. Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The 
International Society for Cellular Therapy position statement. Cytotherapy 8, 315-317 (2006). 
5. Cheng, Z. et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to 
infarcted myocardium improves cardiac performance. Mol. Ther. 16, 571-579 (2008). 
6. Sasportas, L. S. et al. Assessment of therapeutic efficacy and fate of engineered human 
mesenchymal stem cells for cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 106, 4822-4827 
(2009). 
7. Choi, J. -. et al. Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-
induced arthritis in mice. Clin. Exp. Immunol. 153, 269-276 (2008). 
8. Chen, C., Akerstrom, V., Baus, J., Lan, M. S. & Breslin, M. B. Comparative Analysis of the 
Transduction Efficiency of Five AAV Serotypes and Lentiviral Vectors in Lung Cancer Cells. 
Mol. Ther. 20, S97-S97 (2012). 
9. Conwell, C. C. & Huang, L. Recent Advances in Non-viral Gene Delivery. Adv. Genet. 53, 3-
18 (2005). 
10. Savulescu, J. Harm, ethics committees and the gene therapy death. J. Med. Ethics 27, 148-
150 (2001). 
11. Nayak, S. & Herzog, R. W. Progress and prospects: immune responses to viral vectors. Gene 
Ther. 17, 295-304 (2010). 
12. Stiehler, M. et al. Optimizing viral and non-viral gene transfer methods for genetic 
modification of porcine mesenchymal stem cells. Tissue Eng. 585, 31-48 (2006). 
13. Resina, S., Prevot, P. & Thierry, A. R. Physico-Chemical Characteristics of Lipoplexes 
Influence Cell Uptake Mechanisms and Transfection Efficacy. Plos One 4, e6058 (2009). 
14. Weaver, J. & Chizmadzhev, Y. Theory of electroporation: A review. Bioelectrochem. 
Bioenerget. 41, 135-160 (1996). 
62 
 
15. Qiu, Y., Zhang, C., Tu, J. & Zhang, D. Microbubble-induced sonoporation involved in 
ultrasound-mediated DNA transfection in vitro at low acoustic pressures. J. Biomech. 45, 1339-
1345 (2012). 
16. Browning, R. J. et al. Effect of Albumin and Dextrose Concentration on Ultrasound and 
Microbubble Mediated Gene Transfection in Vivo. Ultrasound Med. Biol. 38, 1067-1077 (2012). 
17. Escoffre, J. M., Kaddur, K., Rols, M. P. & Bouakaz, A. In Vitro Gene Transfer by 
Electrosonoporation. Ultrasound in Medicine and Biology 36, 1746-1755 (2010). 
18. Yamashita, Y. et al. Muscle-targeted interleukin-12 gene therapy of orthotopic hepatocellular 
carcinoma in mice using in vivo electrosonoporation. Molecular Cancer Therapeutics 3, 1177-
1182 (2004). 
19. Yamashita, Y. I. et al. In vivo gene transfer into muscle via electro-sonoporation. Hum. Gene 
Ther. 13, 2079-2084 (2002). 
20. Mintzer, M. A. & Simanek, E. E. Nonviral Vectors for Gene Delivery. Chem. Rev. 109, 259-
302 (2009). 
21. Hoare, M. et al. Enhanced lipoplex-mediated gene expression in mesenchymal stem cells 
using reiterated nuclear localization sequence peptides. J. Gene Med. 12, 207-218 (2010). 
22. Hamm, A., Krott, N., Breibach, I., Blindt, R. & Bosserhoff, A. K. Efficient transfection 
method for primary cells. Tissue Eng. 8, 235-245 (2002). 
23. Haleem-Smith, H. et al. Optimization of high-efficiency transfection of adult human 
mesenchymal stem cells in vitro. Mol. Biotechnol. 30, 9-19 (2005). 
24. Aluigi, M. et al. Nucleofection is an efficient nonviral transfection technique for human bone 
marrow-derived mesenchymal stem cells. Stem Cells 24, 454-461 (2006). 
25. Helledie, T., Nurcombe, V. & Cool, S. M. A simple and reliable electroporation method for 
human bone marrow mesenchymal stem cells. Stem Cells Dev. 17, 837-848 (2008). 
26. Madeira, C. et al. Nonviral Gene Delivery to Mesenchymal Stem Cells Using Cationic 
Liposomes for Gene and Cell Therapy. Journal of Biomedicine and Biotechnology, 735349 
(2010). 
27. Lim, J. Y. et al. Microporation is a valuable transfection method for efficient gene delivery 
into human umbilical cord blood-derived mesenchymal stem cells. BMC Biotechnol. 10, 38 
(2010). 
28. McMahon, J. et al. Gene transfer into rat mesenchymal stem cells: A comparative study of 
viral and nonviral vectors. Stem Cells Dev. 15, 87-96 (2006). 
63 
 
29. Song, L. et al. Electric field-induced molecular vibration for noninvasive, high-efficiency 
DNA transfection. Mol. Ther. 9, 607-616 (2004). 
30. Gheisari, Y., Soleimani, M., Azadmanesh, K. & Zeinali, S. Multipotent mesenchymal 
stromal cells: optimization and comparison of five cationic polymer-based gene delivery 
methods. Cytotherapy 10, 815-823 (2008). 
31. Ferreira, E. et al. Optimization of a gene electrotransfer method for mesenchymal stem cell 
transfection. Gene Ther. 15, 537-544 (2008). 
32. Chen, X. et al. Plasmid-encapsulated polyethylene glycol-grafted polyethylenimine 
nanoparticles for gene delivery into rat mesenchymal stem cells. International journal of 
nanomedicine 6, 843-853 (2011). 
33. Cao, X. et al. Encapsulation of plasmid DNA in calcium phosphate nanoparticles: stem cell 
uptake and gene transfer efficiency. Int. J. Nanomed. 6, 3335-3349 (2011). 
34. Deng, W. et al. Efficient Gene Delivery to Mesenchymal Stem Cells by an Ethylenediamine-
Modified Polysaccharide from Mulberry Leaves. Small 8, 441-451 (2012). 
35. Santos, J. L. et al. Receptor-Mediated Gene Delivery Using PAMAM Dendrimers 
Conjugated with Peptides Recognized by Mesenchymal Stem Cells. Mol. Pharm. 7, 763-774 
(2010). 
36. Chu, C. R., Szczodry, M. & Bruno, S. Animal Models for Cartilage Regeneration and Repair. 
Tissue Eng. Part B-Rev. 16, 105-115 (2010). 
37. Schnabel, L. V. et al. Mesenchymal Stem Cells and Insulin-Like Growth Factor-I Gene-
Enhanced Mesenchymal Stem Cells Improve Structural Aspects of Healing in Equine Flexor 
Digitorum Superficialis Tendons. J. Orthop. Res. 27, 1392-1398 (2009). 
38. Wagner, W. et al. Replicative Senescence of Mesenchymal Stem Cells: A Continuous and 
Organized Process. PLoS One 3, e2213 (2008). 
39. Markar, A. Z. Electroporation of Mesenchymal Stem Cells for the Secretion of Factor IX. 
Open Access Dissertations and Theses, Paper 6725 (2012). 
40. Lim, J. Y. et al. Microporation is a valuable transfection method for efficient gene delivery 
into human umbilical cord blood-derived mesenchymal stem cells. BMC Biotechnol. 10, 38 
(2010). 
41. Jacobsen, L. B., Calvin, S. A. & Lobenhofer, E. K. Transcriptional effects of transfection: the 
potential for misinterpretation of gene expression data generated from transiently transfected 
cells. BioTechniques 47, 617-+ (2009). 
  
64 
 
Appendix 1: Supplementary Results 
Table S1. Supplementary Results: Early Lipofectamine LTX & PLUS Reagent and 
XtremeGene HP Optimization.  
The average fluorescence reading ± standard deviation are provided. Note that this is not 
an actual transfection percentage, but is correlated with the actual transfection percentage.  
For XtremeGene, three wells were used for each ratio/volume combination; for 
Lipofectamine, 18 wells were used for each ratio/volume combination. Because the gain setting 
on the plate reader was very low, the XtremeGene results are included as a point of reference.  
It appears that lower volumes of Lipofectamine LTX & PLUS should be tested in the 
future, for they resulted in the highest fluorescence levels for that reagent. Two other interesting 
points to note are that, firstly, in this very early experiment, XtremeGene still produced higher 
fluorescence readings than FuGene (FuGene data not shown); also, the highest fluorescence 
readings within XtremeGene were obtained in the 2:1 and 1:1 ratios, which were later confirmed 
to be the most effective.  
Fluorescence readings greater than 15 fluorescence units are bolded. The leftmost vertical 
column indicates the plating volume per well, in microliters; the ratios across the top indicate the 
reagent-to-DNA ratio.  
 
XtremeGene HP 
Cells-only control=1.06±0.32; XtremeGene-only control=0.87±0.33; DNA-only 
control=0.96±0.24 
Ratio → 
1:1 2:1 3:1 4:1 
Volume ↓ 
2 0.89±0.19 2.33±0.51 4.48±1.39 6.56±2.12 
5 2.78±2.32 13.52±1.41 17.93±5.93 21.67±7.28 
10 4.96±2.92 19.78±10.77 14.37±3.41 10.00±3.76 
15 9.48±0.84 21±1.37 18.48±1.68 10.07±2.00 
20 18.56±8.10 20.59±5.50 18.82±6.91 5.67±2.17 
25 36.15±9.02 19.44±5.40 13.30±8.02 7.5926±1.72 
 
Lipofectamine LTX & PLUS 
Cells-only control=0.74±0.26; Reagent-only control=0.78±0.20; DNA-only 
control=0.76±0.18 
Ratio → 1:1 2:1 3:1 4:1 5:1 6:1 
Volume ↓ 
10 5.19±3.60 13.70±7.50 17.48±4.94 31.04±11.18 20.85±6.14 14.78±12.81 
20 7.30±4.09 1.63±0.57 5.11±6.26 10.41±5.17 8.63±4.06 7.07±3.22 
30 1.41±0.17 3.11±0.87 2.85±0.42 2.96±0.84 0.85±0.26 1.22±0.59 
40 2.22±1.94 1.37±0.74 1.70±0.95 1.59±0.95 1.44±0.84 0.85±0.17 
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Table S2. Supplementary Results: Failure of Expired XtremeGene to Elicit Typical 
XtremeGene Transfection Efficiency. Volume given is the μl added per well of a 96-well plate, 
with each well initially containing 100 μl of media. As demonstrated through the previous 
experiments, regular XtremeGene results in higher fluorescence than FuGene. But here, when 
expired XtremeGene was used, FuGene provided better transfection. Visual observation of 
transfected cells also confirmed the failure of expired XtremeGene to function as effectively as 
usual. Twenty-one wells were used for each particular ratio/volume combination in the table 
above.  
Reagent Ratio (μl of reagent 
to μg of DNA) 
Volume  Fluorescence Reading 
(Average ± St. Dev) 
XtremeGene 
HP 
1:2 28 3.35 ± 1.01 
32 3.73 ± 1.58 
36 3.49 ± 1.41 
1:1 32 149.04 ± 22.78 
36 108.44 ± 24.82 
40 77.97 ± 13.50 
2:1 24 81.62 ± 23.18 
28 49.90 ± 14.12 
32 44.74 ± 9.40 
3:1 8 47.88 ± 42.53 
12 92.62 ± 45.15 
16 65.93 ± 14.66 
FuGene HD 5:2 22.5 204.08 ± 35.36 
Controls (reagent only, DNA 
only, cells only) 
 4.25 ± 1.33 
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Appendix 2: Solution Formulations  
 
10% or 20% Fetal Bovine Serum Mesenchymal Stem Cell Media (with or without antibiotics) 
(Referred to as “FBS MSC media” in the text; unless specifically noted in the text, antibiotics are 
included in the media) 
Add the following to a 500mL bottle of Low Glucose DMEM (HyClone ThermoScientific, 
Logan, UT): 
 12.5 mL HEPES buffer (1 M, 238.3 mg/ml, Cellgro Mediatech Inc., Manassas, VA) 
 50 mL fetal bovine serum (HyClone FBS, Characterized; Canadian sourced. Cat. No. 
SH30396.03) 
 5 mL Pen/Strep (10,000 IU/mL Pen, 10,000 μg/mL Strep, Cellgro Mediatech Inc., 
Manassas, VA. Cat. No. 30-002-CI) 
 25 μl bFGF (100 μg/mL stock suspended in stem cell isolation media; Millipore, 
Danvers, MA) 
Sterile filter into autoclaved bottle with 0.2 μM bottle-top filter. Store at 4°C.  
For 20% FBS MSC media, add 100 mL FBS instead of only 50 ml FBS.  
For antibiotic-free media, exclude Pen/Strep. 
 
 
Mesenchymal Stem Cell Freeze Media 
Combine the following in a glass bottle: 
 80mL stem cell isolation media 
 10 mL fetal bovine serum 
 10mL dimethyl sulfoxide (DMSO) 
Sterile filter into an autoclaved bottle with 0.2 μM bottle-top filter. Do not add ingredients 
through the filter because DMSO will dissolve the filter membrane if added directly to the bottle-
top filter apparatus. Store at -8°C.  
 
 
FACS Sorting Buffer (with 1 mM EDTA and 1% FBS; optional DAPI) 
Add the following to a 500 ml bottle of 1x PBS (Ca/Mg++ free) 
 12.8 ml HEPES buffer (1 molar) 
 0.195 grams EDTA (tetrasodium salt, MW = 380.16) 
 5.2 ml fetal bovine serum (Ca/Mg++-free if possible) 
 5 ml Pen/Strep 
 Optional: add DAPI to obtain a concentration of 1 mg DAPI per 100 ml of sorting buffer. 
Solution should be stirred at 4ºC overnight to increase dissolution of the DAPI.  
Filter sterilize; store at 4ºC 
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Appendix 3: Additional Protocols—MSC Isolation 
 
MSC Isolation (24-hour Split Method)  
This method provides somewhat higher cell numbers at first passage on average than other 
methods but is more labor-intensive. 
Day 0 
1) Pre-warm MSC isolation media in 37°C waterbath. For clinical cases, use 20% Serum 
MSC isolation media. For research cases, it is generally preferred to use the standard 10% 
serum.  
2) Label one flask for every 20 mL of marrow, and add 30 mL of media to each flask. 
Ideally, each flask should be labeled to indicate which syringe was its source. 
3) Clean syringes of marrow with ethanol before bringing into hood. 
4) Add 20 mL of marrow to each flask. 
5) Tilt flasks to make sure entire bottom surface is covered with liquid, being careful not to 
get liquid into the cap. 
6) Place flasks into incubator overnight.  
Day 1 
7) Pre-warm appropriate MSC isolation media in 37°C waterbath 
8) While media is warming, prepare additional flasks equal to the original number of flasks 
9) Add 30 mL of isolation media to the original flasks, rinsing the culture surface as you add 
media 
10) Remove 30-40 mL of the marrow-media mixture from each original flask an add it to a 
correspondingly labeled new flask 
11) Tilt new flasks to make sure entire bottom surface is covered with liquid, being careful 
not to get liquid into the cap 
12) Place all flasks into incubator at least overnight but for no longer than 48 hours 
Day 2 or 3 
13) Pre-warm appropriate MSC isolation media in 37°C water bath. 
14) Aspirate media 
15) Rinse flasks with 10 mL each of HBSS 
16) Aspirate HBSS 
17) Add 30 mL MSC isolation media 
Ongoing 
18) Repeat HBSS rinse 48 hours later if significant blood remains in flask, otherwise simply 
aspirate and feed. For clinical cases, once most blood is removed from plates, it is fine to 
switch to 10% serum standard MSC isolation media 
19) Proceed to aspirate media and feed fresh media every 48 hours until moderately dense 
MSC colonies have formed on the culture surface—typically 5 to 11 days from initial 
plating depending on horse and quality of draw.  
20) Assess number and density of colonies to determine the ideal surface area needed for first 
passage and prepare an appropriate number of plates 
21) Proceed to stem cell passaging protocol 
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MSC Isolation (No Split Method)  
This method is used when it is difficult or impossible for someone to work with the cells 24 
hours after initial plating. 
Day 0 
1) Pre-warm MSC isolation media in 37°C water bath. For clinical cases, use 20% Serum 
MSC isolation media. For research cases, it is generally preferred to use standard 10% 
serum. 
2) Label one flask for every 10 mL of marrow, and add 30 mL of media to each flask. 
Ideally, each flask should be labeled to indicate which syringe was its source. 
3) Clean syringes of marrow with ethanol before bringing into hood 
4) Add 10 mL of marrow to each flask 
5) Tilt flasks to make sure entire bottom surface is covered with liquid, being careful not to 
get liquid into the cap 
6) Place flasks into incubator at least overnight but for no longer than 48 hours 
Day 1 
7) Pre-warm appropriate MSC isolation media in 37°C water bath 
8) Aspirate media 
9) Add 30 mL MSC isolation media 
10) Place flasks into incubator at least overnight but for no longer than 48 hours  
Day 2 or 3 
11) Pre-warm appropriate MSC isolation media in 37°C water bath 
12) Rinse flasks with 10mL each of HBSS 
13) Aspirate HBSS 
14) Add 30 mL MSC isolation media 
Ongoing 
15) Repeat HBSS rinse 48 hours later if significant blood remains in flask. Otherwise simply 
aspirate and feed. For clinical cases, once most blood is removed from plates, it is fine to 
switch to 10% serum standard MSC isolation media 
16) Proceed to aspirate media and feed fresh media every 48 hours until moderately dense 
MSC colonies have formed on the culture surface, typically 5 to 11 days from initial 
plating depending on horse and quality of draw 
17) Assess number and density of colonies to determine the idea surface area needed for first 
passage and prepare an appropriate number of plates 
18) Proceed to stem cell passaging protocol 
 
 
 
 
